Sacituzumab govitecan

Drug Profile

Sacituzumab govitecan

Alternative Names: anti-TROP-2-SN-38; Anti-TROP-2-SN-38 conjugate; hRS7-SN 38; hRS7-SN38 antibody drug conjugate; IMMU-132; Isactuzumab govitecan; TROP-2-SN-38

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators; TROP2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Solid tumours
  • Preclinical Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 05 May 2017 Sacituzumab govitecan is available for licensing as of 05 May 2017. www.immunomedics.com
  • 05 May 2017 Seattle Genetics terminates the exclusive agreement with Immunomedics to license Sacituzumab govitecan worldwide
  • 05 May 2017 Immunomedics announces intention to submit BLA with the US FDA for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top